Cha Vaccine Institute has constructed the next-generation immune booster platform to develop next-generation vaccines and immunotherapy medications. The pipelines consist of clinical trial phase 2b approval for hepatitis B treatment vaccine in Korea, and clinical trial phase 1 approval for hepatitis B prevention vaccine in Korea.
Location: South Korea, Gyeonggi, Seongnam-si
Employees: 11-50
Founded date: 2000
Investors 1
| Date | Name | Website |
| - | UTC Invest... | utc.co.kr |
Mentions in press and media 1
| Date | Title | Description | Source |
| 08.09.2022 | BioLingus and partners secure research grant for needle-free... | The granted R&D project “Development of sublingual COVID-19 subunit vaccine” aims to develop a... | startuptic... |